An update of cyclooxygenase (COX)-inhibitors in epilepsy disorders. (1st February 2019)

• Record Type: Journal Article
• Authors: Dhir, Ashish
• Is Part Of: Expert opinion on investigational drugs. Volume 28:Number 2(2019)
• Page Start: 191
• Page End: 205
• Publication Date: 2019-02-01
• Subjects: Cyclooxygenase (COX) -- epilepsy -- spontaneous recurrent seizures -- antiepileptic -- antiepileptogenic -- proconvulsant; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2019.1557147
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : Neuroinflammation has a critical role in brain disorders. Cyclooxygenase (COX) is one of the principal drug targets for the reduction of neuroinflammation; however, studies have yielded mixed results for COX-inhibitors in the treatment of diverse acute and chronic models of epilepsy. Areas covered : The article covers the effects of COX-inhibitors in epilepsy disorders. A considerable emphasis has been placed on the antiepileptic and 'disease-modifying' properties of COX-1 and COX-2 inhibitors in various preclinical epilepsy models. Expert opinion : The effect of COX-inhibitors on epilepsy is inconclusive. Studies have indicated beneficial effects in preclinical models; however, proconvulsant or no effects have also been observed. These molecules may have a bidirectional role with early neuroprotective and delayed neurotoxic effects. Further systematic preclinical studies to establish the use of COX-inhibitors in epilepsy are necessary.